Number 5: Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees ...

Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced ...

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

Number 5: Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for patients with inflammatory bowel disease (IBD). Number 4: Significant knowledge ...

Aislinn Antrim serves as Managing Editor at Pharmacy Times.

Pediatric patients with inflammatory bowel disease (IBD) treated with adalimumab biosimilars had “high durability and remission rates” at a lower cost of treatment, according to a real-world study in ...